Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00013925
DRKS00013925
Completed
未知

Early evaluation of therapy response (targeted therapy and immunotherapy) in patients with metastasized malignant melanoma by multiparametric PET/MR imaging. - GK-MR/PET Tü-004

niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie0 sites62 target enrollmentJanuary 29, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC43.9Malignant melanoma of skin, unspecified

Overview

Phase
未知
Intervention
Not specified
Conditions
C43.9
Sponsor
niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie
Enrollment
62
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 29, 2018
End Date
September 3, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie

Eligibility Criteria

Inclusion Criteria

  • •Patient with diagnosed unresectable malignant melanoma stage IV,
  • •\-Age: \=18 years,
  • •\-Planned systemic therapy with new therapies: BRAF/MEK inhibitors, Anti\-CTLA\-4/Anti\-PD\-1 antibodies,
  • •\-Clinically indicated routine PET/CT (baseline t0\) demonstrating at least one measurable lesion,
  • •\-PET/CT for baseline\-staging and therapy monitoring (clinical indication required),
  • •\-Informed consent.

Exclusion Criteria

  • •\-Contraindications for MR\-imaging (metal implants, claustrophobia, etc.),
  • •\-Contraindications for gadolinium\-based contrast agent,
  • •\-Acute infections or other acute diseases,
  • •\-Pregnant or breast\-feeding women,
  • •\-Disability for informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Evaluation of early treatment response and volumetric dose evaluation to target and organ at risk (small bowel/bladder/rectum) during radiation therapy of cervical cancer.Health Condition 1: null- GOODHealth Condition 2: C539- Malignant neoplasm of cervix uteri, unspecified
CTRI/2022/03/040851AIIMS21
Recruiting
Phase 1
The efficacy assessment of 225Ac-PSMA-617 in Prostate cancer treatment.
IRCT20211206053304N2Iran University of Medical Sciences10
Recruiting
Not Applicable
ERASE_Evaluation of early treatment response of soft tissue sarcomas under neoadjuvant hyperthermia and chemotherapy using functional MRI as well as FDG PET-CTC41.9C41Bone and articular cartilage, unspecifiedMalignant neoplasm of bone and articular cartilage of other and unspecified sites
DRKS00016070Klinikum der Universität München, Campus Großhadern35
Not yet recruiting
Not Applicable
VAI pilot studie in glioblastome
NL-OMON21865niversity Medical Center Groningen (departments of radiology and ngmb)10
Completed
Not Applicable
Pilot study for the treatment response evaluation in glioblastoma with vessel architectural imaging (VAI)
NL-OMON46808niversitair Medisch Centrum Groningen10